No actionable trading signal. This is a standard post-annual meeting filing with routine director elections and equity plan amendments. Monitor for operational or pipeline updates from upcoming earnings or press releases.
Price Chart
Executive Summary
Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approved amendments to the company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to include pre-funded warrants in the evergreen share calculation. Two Class II directors were elected and Ernst & Young was ratified as auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan, adding pre-funded warrants to the evergreen formula's outstanding share count.
- Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were elected as Class II directors.
- Ernst & Young LLP was ratified as independent auditor for fiscal year 2026.
- 38,820,616 shares outstanding as of record date April 13, 2026; 33,190,234 shares present at meeting.
- The 2021 Plan Amendment passed with 14,686,713 for, 9,566,186 against; the ESPP Amendment passed with 16,780,217 for, 7,475,514 against.
Financial Impact
No financial impact. The equity plan amendments are administrative and do not change share reserve amounts or dilutive limits directly.
Risk Factors
- No material risks identified in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072326 |
| Document: tm2617532d1_ex10-1.htm | 0001104659-26-072326 |
| Document: tm2617532d1_ex10-2.htm | 0001104659-26-072326 |
| Document: 0001104659-26-072326-index-headers.html | 0001104659-26-072326 |
| Document: 0001104659-26-072326-index.html | 0001104659-26-072326 |
| Document: 0001104659-26-072326.txt | 0001104659-26-072326 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | Insider Cluster | $6.42 $6.90 | ▼ −7.48% | ▼ −7.98% | $5.38 (+16.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $7.17 $6.80 | ▼ −5.16% | ▼ −4.01% | $5.38 (−24.97%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 27, 2026 5w ago | Insider Cluster | $7.27 $7.17 | ▼ −1.38% | ▼ −1.64% | $5.38 (−26.00%) |
Aug 10, 2026 7w ago | Insider Cluster | $7.04 $7.27 | ▲ +3.27% | ▲ +3.67% | $5.38 (−23.58%) |
Aug 5, 2026 8w ago | 8-K | $7.06 $7.67 | ▲ +8.64% | ▲ +8.29% | $5.38 (−23.80%) |
Aug 3, 2026 8w ago | Insider Cluster | $7.24 $7.04 | ▼ −2.76% | ▼ −2.66% | $5.38 (−25.69%) |
Jul 30, 2026 9w ago | 144 | $6.79 $6.87 | ▼ −1.18% | ▲ +2.33% | $5.38 (+20.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access